KR900004330A - 약물/침투 증대제 조성물과 관련된 피부자극의 감소방법 - Google Patents
약물/침투 증대제 조성물과 관련된 피부자극의 감소방법 Download PDFInfo
- Publication number
- KR900004330A KR900004330A KR1019890011531A KR890011531A KR900004330A KR 900004330 A KR900004330 A KR 900004330A KR 1019890011531 A KR1019890011531 A KR 1019890011531A KR 890011531 A KR890011531 A KR 890011531A KR 900004330 A KR900004330 A KR 900004330A
- Authority
- KR
- South Korea
- Prior art keywords
- composition
- glycerin
- enhancer composition
- enhancer
- drug
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
Abstract
내용 없음
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
Claims (21)
- (a) 경피식으로 흡수가능한 약물, (b) C₂또는 C₃알코올, C₃또는 C₄디올, DMSO, DMF, 음, 1-n-도데실-시클라자시클로헵탄-2-온, N-메틸-피롤리돈 및 N-(2-히드록시에틸)피롤리돈 및 이들의 혼합물로 구성된 그룹에서 선택한 용매 그리고 세포의 포 장해 화합물로 구성된 증대제 조성물 그리고 (c) 자극을 감소시키는데 효과있는 양의 글리세린으로 필수적으로 구성된 약물/증대제 조성물의 유효량을 피부의 예정된 면에 도포하는 것을 포함하는 피부자극 성질을 가지는 약물/증대제 조성물에 의해 야기된 피부자극 감소방법.
- 제1항에 있어서, 세포외막 장해화합물이 라우린산메틸, 올레인산, 올레일 알코올, 일올레인산 글리세롤, 이올레인산, 글리세롤 및 삼올레인산 글리세롤 및 이들의 혼합물로 구성된 그룹에서 선택된 구성부분(member)인 방법.
- 제1항 및 제2항에 있어서, 글리세린 함유 약물/증대제 조성물을 이환위치에 주여하는 방법.
- 제1항 및 제2항에 있어서, 글리세린 함유 약물/증대제 조성물을 증검시키고 피부와 접촉시켜 유지시키는 저장기 속에 넣어서 저장기 바닥을 형성하는 투과성막을 통해 도포위치에서 피부표면에 투여하는 방법.
- 제1항 및 제4항에 있어서, 글리세린 함유 약물/증대제 조성물이 약 0.1 내지 70중량% 글리세린을 포함하는 방법.
- 제1항 내지 제4항에 있어서, 글리세린 함유 약물/증대제 조성물이 약 1.0 내지 50중량%의 글리세린을 포함하는 방법.
- 제1항 내지 제4항에 있어서, 약물/증대제 조성물이 약 5.0 내지 20.0중량%의 글리세린을 포함하는 방법.
- (a) 경피식 흡수가능한 약물, (b) C₂또는 C₃알코올, C₃또는 C₄디올, DMSO, DMF, 음, 1-n-도데실-시클라자시클로헵탄-2-온, N-메틸-피롤리돈 및 N-(2-히드록시에틸)피롤리돈 및 이들의 혼합물로 구성된 그룹에서 선택한 용매 그리고 세포외막 장해 화합물의 효능있는 증대제 량으로서 필수적으로 구성된 증대제 조성물 그리고 (c) 자극을 감소시키는데 효과있는 양의 글리세린으로 필수적으로 구성된 감소된 피부자극 성질을 가지는 약물을 경피식으로 투여하는 약물/증대제 조성물
- 제8항에 있어서, 세포-외막 장해 화합물이 라우린산 메틸, 올레인산, 올레인산 알코올, 일올레인산 글리세롤, 이올레인산 글리세롤 및 심올레인산 글리세롤 및 이들의 혼합물로 구성된 그룹에서 선택된 구성부분인 조성물.
- 제8항 및 제9항에 있어서, 증대제 조성물이 용매로서 에탄올로 포함하는 조성물.
- 제8항 및 제9항에 있어서, 증대제 조성물이 용매로서 DMSO를 포함하는 조성물.
- 제8항 및 제9항에 있어서, 증대제 조성물이 용매로서 프로필렌 글리콜을 포함하는 조성물.
- 제8항 및 제9항에 있어서, 증대제 조성물이 용매로서 1-도데실-아자시클로헵탄-2-온을 포함하는 조성물.
- 제8항 및 제9항에 있어서, 증대제 조성물이 용매로서 프로필렌 글리콜을 포함하는 조성물.
- 제10 내지 제14항에 있어서, 증대제 조성물이 세포-외막 장해 화합물로서 라우린산메틸을 포함하는 조성물.
- 제10 내지 제14항에 있어서, 증대제 조성물이 세포-외막 장해 화합물로서 이올레인산 글리세롤을 포함하는 조성물.
- 제10 내지 제14항에 있어서, 증대제 조성물이 세포-외막 장해 화합물로서 일올레인산 글리세롤을 포함하는 조성물.
- 제10 내지 제14항에 있어서, 증대제 조성물이 세포-외막 장해 화합물로서 올레인산을 포함하는 조성물.
- 제8항 내지 제18항에 있어서, 글리세린이 약 0.1 내지 70.0중량% 범위의 양으로 존재하는 조성물.
- 제8항 내지 제18항에 있어서, 글리세린이 약 1.0 내지 50.0중량%의 범위의 양으로 존재하는 조성물.
- 제8항 내지 제18항에 있어서, 글리세린이 약 5.0 내지 약 20.0중량% 범위의 양으로 존재한 조성물.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US240,688 | 1988-09-06 | ||
US07/240,688 US4855294A (en) | 1988-09-06 | 1988-09-06 | Method for reducing skin irritation associated with drug/penetration enhancer compositions |
Publications (2)
Publication Number | Publication Date |
---|---|
KR900004330A true KR900004330A (ko) | 1990-04-12 |
KR0143916B1 KR0143916B1 (ko) | 1998-07-15 |
Family
ID=22907535
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019890011531A KR0143916B1 (ko) | 1988-09-06 | 1989-08-12 | 약물/침투 증대제 조성물과 관련된 피부자극의 감소방법 |
Country Status (8)
Country | Link |
---|---|
US (1) | US4855294A (ko) |
EP (1) | EP0416137B1 (ko) |
JP (1) | JP2953625B2 (ko) |
KR (1) | KR0143916B1 (ko) |
AT (1) | ATE96678T1 (ko) |
CA (1) | CA1332570C (ko) |
DE (1) | DE68910520T2 (ko) |
ES (1) | ES2053882T3 (ko) |
Families Citing this family (98)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE59101404D1 (de) * | 1990-01-10 | 1994-05-26 | Hoffmann La Roche | Topische Präparate. |
US5160741A (en) * | 1990-07-06 | 1992-11-03 | Alza Corporation | Reduction or prevention of skin irritation by drugs |
US5130139A (en) * | 1990-07-06 | 1992-07-14 | Alza Corporation | Reduction or prevention of skin irritation by drugs |
US5152997A (en) * | 1990-12-11 | 1992-10-06 | Theratech, Inc. | Method and device for transdermally administering testosterone across nonscrotal skin at therapeutically effective levels |
US5518734A (en) * | 1991-09-25 | 1996-05-21 | Beta Pharmaceuticals Co. | Transdermal delivery system for estradiol and process for manufacturing said device |
US5705185A (en) * | 1991-09-25 | 1998-01-06 | Beta Pharmaceuticals Co. | Transdermal delivery of estradiol and process for manufacturing said device |
US5276079A (en) * | 1991-11-15 | 1994-01-04 | Minnesota Mining And Manufacturing Company | Pressure-sensitive poly(n-vinyl lactam) adhesive composition and method for producing and using same |
US6284754B1 (en) * | 1992-01-20 | 2001-09-04 | Schwarz Pharma Ag | Pharmaceutical compositions containing 1-oleylazacycloheptan-2-one as enhancing agent of transport across biological membranes |
AU677206B2 (en) * | 1992-06-11 | 1997-04-17 | Theratech, Inc. | The use of glycerin in moderating transdermal drug delivery |
ES2180546T3 (es) * | 1992-07-23 | 2003-02-16 | Hisamitsu Pharmaceutical Co | Composicion basica administrable percutaneamente y composicion de farmaco preparada a partir de ella. |
DE4429667C2 (de) * | 1994-08-20 | 1996-07-11 | Lohmann Therapie Syst Lts | Estradiol-TTS mit wasserbindenden Zusätzen und Verfahren zu seiner Herstellung |
DE19610396C2 (de) * | 1996-03-16 | 1998-11-26 | Krewel Meuselbach Gmbh | Dimethylsulfoxid-haltige topische Zubereitung |
JP2001503062A (ja) * | 1996-10-30 | 2001-03-06 | セラテック・インコーポレーテッド | 透過促進剤としての乳酸の脂肪酸エステルの塩 |
DE19701949A1 (de) * | 1997-01-13 | 1998-07-16 | Jenapharm Gmbh | Transdermales therapeutisches System |
ZA984649B (en) * | 1997-06-13 | 1999-12-17 | Cryopreservation Tech Cc | "Drug delivery devices and methods for treatment of viral and microbial infections and wasting syndromes". |
PT1510213E (pt) | 1997-11-10 | 2009-02-12 | Strakan Internat Ltd Uma Socie | Sistemas de melhoramento de penetração e reduzida irritação incluíndo testosterona |
US6180133B1 (en) * | 1997-11-25 | 2001-01-30 | Watson Pharmaceuticals, Inc. | Antioxidant composition for topical/transdermal prevention and treatment of wrinkles |
US6136799A (en) * | 1998-04-08 | 2000-10-24 | Abbott Laboratories | Cosolvent formulations |
EP1094781B1 (en) * | 1998-07-07 | 2008-07-02 | Transdermal Technologies Inc. | Compositions for rapid and non-irritating transdermal delivery of pharmaceutically active agents and methods for formulating such compositions and delivery thereof |
US7179475B1 (en) | 1998-12-04 | 2007-02-20 | Johnson & Johnson Consumer Companies, Inc. | Anhydrous topical skin preparations |
US6238683B1 (en) * | 1998-12-04 | 2001-05-29 | Johnson & Johnson Consumer Companies, Inc. | Anhydrous topical skin preparations |
AU5460800A (en) * | 1999-06-02 | 2000-12-18 | Aviana Biopharm | Pharmaceutical transdermal compositions |
US6232366B1 (en) | 1999-06-09 | 2001-05-15 | 3M Innovative Properties Company | Pressure sensitive conductive adhesive having hot-melt properties and biomedical electrodes using same |
KR100369779B1 (ko) * | 1999-07-12 | 2003-01-29 | 주식회사 엘지생명과학 | 교감신경 흥분성 기관지확장 약물의 경피흡수 투여용 조성물및 이를 포함하는 경피흡수 투여용 제형 |
US7179483B2 (en) * | 2000-04-26 | 2007-02-20 | Watson Pharmaceuticals, Inc. | Compositions and methods for transdermal oxybutynin therapy |
ATE338538T1 (de) * | 2000-05-01 | 2006-09-15 | Johnson & Johnson Consumer | Wasserfreie topische zubereitungen für die haut |
US20060121103A1 (en) * | 2000-05-11 | 2006-06-08 | Kenneth Kirby | Transdermal delivery system |
US8512718B2 (en) | 2000-07-03 | 2013-08-20 | Foamix Ltd. | Pharmaceutical composition for topical application |
DE10040592A1 (de) * | 2000-08-15 | 2002-03-07 | Aventis Res & Tech Gmbh & Co | Formulierung zur verbesserten Aufnahme von Wirkstoffen und deren Verwendung |
JP4358978B2 (ja) * | 2000-09-05 | 2009-11-04 | 日東電工株式会社 | 経皮吸収製剤 |
KR20030028253A (ko) * | 2001-09-27 | 2003-04-08 | (주)지씨아이 | 잔탄검과 알긴을 이용한 항고지단백혈증 경피투과제제의제조 |
US7921999B1 (en) | 2001-12-20 | 2011-04-12 | Watson Laboratories, Inc. | Peelable pouch for transdermal patch and method for packaging |
US6765001B2 (en) * | 2001-12-21 | 2004-07-20 | Medicis Pharmaceutical Corporation | Compositions and methods for enhancing corticosteroid delivery |
IL152486A0 (en) | 2002-10-25 | 2003-05-29 | Meir Eini | Alcohol-free cosmetic and pharmaceutical foam carrier |
US8900554B2 (en) | 2002-10-25 | 2014-12-02 | Foamix Pharmaceuticals Ltd. | Foamable composition and uses thereof |
KR101108439B1 (ko) | 2002-10-25 | 2012-01-31 | 포믹스 리미티드 | 화장료 및 약제용 거품제 |
US10117812B2 (en) | 2002-10-25 | 2018-11-06 | Foamix Pharmaceuticals Ltd. | Foamable composition combining a polar solvent and a hydrophobic carrier |
US7700076B2 (en) | 2002-10-25 | 2010-04-20 | Foamix, Ltd. | Penetrating pharmaceutical foam |
US7704518B2 (en) | 2003-08-04 | 2010-04-27 | Foamix, Ltd. | Foamable vehicle and pharmaceutical compositions thereof |
US9211259B2 (en) | 2002-11-29 | 2015-12-15 | Foamix Pharmaceuticals Ltd. | Antibiotic kit and composition and uses thereof |
US7820145B2 (en) | 2003-08-04 | 2010-10-26 | Foamix Ltd. | Oleaginous pharmaceutical and cosmetic foam |
US9668972B2 (en) | 2002-10-25 | 2017-06-06 | Foamix Pharmaceuticals Ltd. | Nonsteroidal immunomodulating kit and composition and uses thereof |
US9265725B2 (en) | 2002-10-25 | 2016-02-23 | Foamix Pharmaceuticals Ltd. | Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof |
US8486376B2 (en) | 2002-10-25 | 2013-07-16 | Foamix Ltd. | Moisturizing foam containing lanolin |
US8119150B2 (en) | 2002-10-25 | 2012-02-21 | Foamix Ltd. | Non-flammable insecticide composition and uses thereof |
US8119109B2 (en) | 2002-10-25 | 2012-02-21 | Foamix Ltd. | Foamable compositions, kits and methods for hyperhidrosis |
US20080138296A1 (en) | 2002-10-25 | 2008-06-12 | Foamix Ltd. | Foam prepared from nanoemulsions and uses |
US7575739B2 (en) | 2003-04-28 | 2009-08-18 | Foamix Ltd. | Foamable iodine composition |
US20040247654A1 (en) * | 2003-06-05 | 2004-12-09 | 3M Innovative Properties Company | Hydrophilic adhesives for delivery of herbal medicines |
US9278155B2 (en) | 2003-06-05 | 2016-03-08 | 3M Innovative Properties Company | Adhesive compositions, articles incorporating same and methods of manufacture |
JP4596751B2 (ja) * | 2003-06-11 | 2010-12-15 | 帝國製薬株式会社 | 消炎鎮痛貼付剤 |
US8486374B2 (en) | 2003-08-04 | 2013-07-16 | Foamix Ltd. | Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses |
US8795693B2 (en) | 2003-08-04 | 2014-08-05 | Foamix Ltd. | Compositions with modulating agents |
DE102004009903A1 (de) | 2004-02-26 | 2005-09-22 | Grünenthal GmbH | Pflaster mit reduzierter Hautirritation |
JP5179879B2 (ja) * | 2004-11-29 | 2013-04-10 | アンブリア ダーマトロジー アクティエボラーグ | 組成物 |
EP1827375A4 (en) * | 2004-12-02 | 2012-09-05 | Omp Inc | SYSTEM FOR IMPROVED PERCUTANEOUS USE OF SKIN USEFUL AGENTS |
US7999023B2 (en) | 2004-12-03 | 2011-08-16 | 3M Innovative Properties Company | Process for making pressure sensitive adhesive hydrogels |
US10137135B2 (en) | 2005-08-15 | 2018-11-27 | Allergan Sales, Llc | Formulations and methods for providing progestin-only contraception while minimizing adverse side effects associated therewith |
US8147815B2 (en) | 2005-12-16 | 2012-04-03 | Celmatrix Corporation | Topical administration carrier composition and therapeutic formulations comprising same |
US20070179121A1 (en) * | 2006-02-02 | 2007-08-02 | Plott R T | Method of treating pediatric patients with corticosteroids |
US7905852B2 (en) | 2006-05-16 | 2011-03-15 | Barbara Jennings-Spring | Skin-contacting-adhesive free dressing |
US7645252B2 (en) * | 2006-05-16 | 2010-01-12 | Barbara Brooke Jennings-Spring | Body or plant part dressing |
MX2009004038A (es) | 2006-10-17 | 2009-08-24 | Nuvo Res | Gel de diclofenaco. |
US20080260655A1 (en) | 2006-11-14 | 2008-10-23 | Dov Tamarkin | Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses |
US20080152592A1 (en) * | 2006-12-21 | 2008-06-26 | Bayer Healthcare Llc | Method of therapeutic drug monitoring |
ES2753850T3 (es) * | 2007-01-29 | 2020-04-14 | Nat Res Council Canada | Uso de catecolaminas y compuestos relacionados como agentes antiangiogénicos |
KR101521989B1 (ko) * | 2007-03-02 | 2015-05-28 | 테이카 세이야쿠 가부시키가이샤 | 경피흡수 의약조성물, 의약조성물 저장유닛 및 이것을 이용하는 경피흡수제제 |
WO2008115224A2 (en) * | 2007-03-20 | 2008-09-25 | Bayer Healthcare Llc | Method of analyzing an analyte |
US8636982B2 (en) | 2007-08-07 | 2014-01-28 | Foamix Ltd. | Wax foamable vehicle and pharmaceutical compositions thereof |
WO2009069006A2 (en) | 2007-11-30 | 2009-06-04 | Foamix Ltd. | Foam containing benzoyl peroxide |
WO2009072007A2 (en) | 2007-12-07 | 2009-06-11 | Foamix Ltd. | Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof |
US8518376B2 (en) | 2007-12-07 | 2013-08-27 | Foamix Ltd. | Oil-based foamable carriers and formulations |
EP2230911A4 (en) * | 2007-12-21 | 2013-07-03 | Zars Pharma Inc | STAMPS, FORMULATIONS, AND RELATED METHODS FOR THE TRANSDERMAL DELIVERY OF ALPRAZOLAM AND OTHER MEDICAMENTS |
CA2712120A1 (en) | 2008-01-14 | 2009-07-23 | Foamix Ltd. | Poloxamer foamable pharmaceutical compositions with active agents and/or therapeutic cells and uses |
US8618164B2 (en) | 2009-03-31 | 2013-12-31 | Nuvo Research Inc. | Treatment of pain with topical diclofenac compounds |
US8546450B1 (en) | 2009-03-31 | 2013-10-01 | Nuvo Research Inc. | Treatment of pain with topical diclofenac compounds |
CA2760186C (en) | 2009-04-28 | 2019-10-29 | Foamix Ltd. | Foamable vehicle and pharmaceutical compositions comprising aprotic polar solvents and uses thereof |
WO2011013009A2 (en) | 2009-07-29 | 2011-02-03 | Foamix Ltd. | Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses |
CA2769677A1 (en) | 2009-07-29 | 2011-02-03 | Foamix Ltd. | Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses |
EP2482788B1 (en) | 2009-10-02 | 2022-12-14 | Journey Medical Corporation | Topical tetracycline compositions |
US9849142B2 (en) | 2009-10-02 | 2017-12-26 | Foamix Pharmaceuticals Ltd. | Methods for accelerated return of skin integrity and for the treatment of impetigo |
US8174881B2 (en) | 2009-11-24 | 2012-05-08 | Micron Technology, Inc. | Techniques for reducing disturbance in a semiconductor device |
KR20150111970A (ko) | 2013-01-24 | 2015-10-06 | 아이리듬 테크놀로지스, 아이엔씨 | 생리학적 모니터링 기기 |
MX2016003922A (es) | 2013-09-30 | 2016-06-17 | 3M Innovative Properties Co | Copolimeros de silicona-polieter, adhesivos y articulos medicos que los comprenden, y metodos para elaborarlos. |
EP3212061B1 (en) | 2014-10-31 | 2023-06-07 | Irhythm Technologies, Inc. | Physiological monitoring system |
WO2017044458A1 (en) * | 2015-09-08 | 2017-03-16 | The University Of Toledo | Treatment of raynaud's phenomenon by inhibition of transient receptor potential melastatin-8 (trpm-8) |
CN113413375A (zh) * | 2016-05-30 | 2021-09-21 | 傅远桥 | 皮肤多种损伤创面治疗的外用药物组合物及其制备方法 |
US10398641B2 (en) | 2016-09-08 | 2019-09-03 | Foamix Pharmaceuticals Ltd. | Compositions and methods for treating rosacea and acne |
US10736905B1 (en) | 2016-09-09 | 2020-08-11 | Shahin Fatholahi | Nefopam dosage forms and methods of treatment |
US9962444B2 (en) | 2016-09-27 | 2018-05-08 | Shane Malek | Pharmacokinetically extended action topical hair growth formulation, and administration method |
US10702495B2 (en) | 2017-02-20 | 2020-07-07 | Nexien Biopharma, Inc. | Method and compositions for treating dystrophies and myotonia |
US10736874B1 (en) | 2017-09-08 | 2020-08-11 | Shahin Fatholahi | Methods for treating pain associated with sickle cell disease |
US11446311B2 (en) | 2017-09-08 | 2022-09-20 | Shahin Fatholahi | Methods for treating pain associated with sickle cell disease |
US20220154041A1 (en) | 2019-04-01 | 2022-05-19 | 3M Innovative Properties Company | Process for making pressure sensitive adhesive hydrogels |
EP3750528A1 (en) | 2019-06-11 | 2020-12-16 | Nexien Biopharma, Inc. | Compositions for treating dystrophies and myotonia |
CA3171482C (en) | 2020-02-12 | 2024-03-26 | Irhythm Technologies, Inc | Non-invasive cardiac monitor and methods of using recorded cardiac data to infer a physiological characteristic of a patient |
AU2021322280A1 (en) | 2020-08-06 | 2023-04-06 | Irhythm Technologies, Inc. | Adhesive physiological monitoring device |
AU2021320404A1 (en) | 2020-08-06 | 2023-04-06 | Irhythm Technologies, Inc. | Electrical components for physiological monitoring device |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1408384A (en) * | 1920-06-21 | 1922-02-28 | Thomas J Newlyn | Cosmetic lotion |
CA1165240A (en) * | 1980-07-09 | 1984-04-10 | The Procter & Gamble Company | Penetrating topical pharmaceutical compositions |
EP0095813A3 (en) * | 1982-06-01 | 1985-05-08 | THE PROCTER & GAMBLE COMPANY | Penetrating topical pharmaceutical compositions containing 9-(2-hydroxyethoxymethyl) guanine |
GR77517B (ko) * | 1982-06-30 | 1984-09-24 | Procter & Gamble | |
EP0105657B1 (en) * | 1982-09-30 | 1992-05-27 | Lancaster Group Ag | Cosmetic compositions containing glycerine |
US4537776A (en) * | 1983-06-21 | 1985-08-27 | The Procter & Gamble Company | Penetrating topical pharmaceutical compositions containing N-(2-hydroxyethyl) pyrrolidone |
CA1248450A (en) * | 1984-04-05 | 1989-01-10 | Kazuo Kigasawa | Soft patch |
DE3779999T2 (de) * | 1986-11-14 | 1992-12-10 | Theratech Inc | Erhoehung des penetrationsvermoegens mittels eines aus die zellhuelle veraendernden substanzen und kurzkettigen alkoholen bestehenden binaeren systems. |
-
1988
- 1988-09-06 US US07/240,688 patent/US4855294A/en not_active Expired - Lifetime
-
1989
- 1989-08-08 ES ES89114676T patent/ES2053882T3/es not_active Expired - Lifetime
- 1989-08-08 EP EP89114676A patent/EP0416137B1/en not_active Expired - Lifetime
- 1989-08-08 DE DE89114676T patent/DE68910520T2/de not_active Expired - Fee Related
- 1989-08-08 AT AT89114676T patent/ATE96678T1/de not_active IP Right Cessation
- 1989-08-12 KR KR1019890011531A patent/KR0143916B1/ko not_active IP Right Cessation
- 1989-09-05 JP JP1228476A patent/JP2953625B2/ja not_active Expired - Lifetime
- 1989-09-05 CA CA000610288A patent/CA1332570C/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
US4855294A (en) | 1989-08-08 |
KR0143916B1 (ko) | 1998-07-15 |
EP0416137A1 (en) | 1991-03-13 |
EP0416137B1 (en) | 1993-11-03 |
ES2053882T3 (es) | 1994-08-01 |
DE68910520T2 (de) | 1994-04-07 |
DE68910520D1 (de) | 1993-12-09 |
ATE96678T1 (de) | 1993-11-15 |
JPH02115131A (ja) | 1990-04-27 |
JP2953625B2 (ja) | 1999-09-27 |
CA1332570C (en) | 1994-10-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR900004330A (ko) | 약물/침투 증대제 조성물과 관련된 피부자극의 감소방법 | |
AU568590B2 (en) | Penetration enhancers for transdermal drug delivery of systemic agents | |
US4942158A (en) | Transdermal steroid penetrant compositions and methods utilizing isopropanol and isobutanol | |
ES2042527T3 (es) | Un metodo para preparar una composicion farmaceutica aumentadora de la penetracion para la aplicacion topica. | |
EP0178140A2 (en) | Transdermal therapeutic systems for the administration of nalozone, naltrexone and nalbuphine | |
KR840009035A (ko) | 피부 침투 치료 시스템용 매트릭스 조성물 | |
LU91973I2 (fr) | Fentanyl | |
DZ1067A1 (fr) | Nouvelles préparations pharmaceutiques à emission prolongée. | |
BR9909796B1 (pt) | "derivados de piperidinopirimidina para aplicação tópica" | |
ES2086353T3 (es) | Sistema terapeutico percutaneo que contiene como componente activo buprenorfina. | |
ATE184473T1 (de) | Verwendung von glyzerin zur dämpfung der transdermalen arzneimittelverabreichung | |
US5438067A (en) | Medetomidine preparations for transdermal administration | |
KR960704579A (ko) | 옥시부티닌용 모노글리세리드/락테이트 에스테르 투과 촉진제(Monoglyceride/lactate Ester Permeation Enhancer for Oxybutynin) | |
KR930007445A (ko) | 국소 적용 배합물의 침투 증가방법 | |
KR850004389A (ko) | 경피침투가 증진된 생리학적 활성제제의 제조방법 | |
CA2360300C (en) | A transdermal composition of an antivomiting agent and a preparation containing the same | |
EP0651993B1 (en) | Percutaneously administrable base composition and drug composition prepared therefrom | |
US4777047A (en) | Transdermal application form of calcium antagonists | |
US5464628A (en) | Pharmaceutical compositions containing 4-substituted imidazoles to be administered transdermally | |
US5422118A (en) | Transdermal administration of amines with minimal irritation and high transdermal flux rate | |
DE19906977C1 (de) | Desoxypeganin-TTS und seine Verwendung | |
JPH03505835A (ja) | 経皮ドラッグデリバリーシステム | |
KR880005946A (ko) | 전신 약품의 경피 투여용 침투 증강제 | |
KR920700704A (ko) | pH-조절된 조건하 약리학적 화합물 투여용 개선된 경피체계 | |
KR100390870B1 (ko) | 경피투여용 항구토제 조성물 및 이를 포함하는 제제 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20120328 Year of fee payment: 15 |
|
EXPY | Expiration of term |